0.627 USD
-0.16 (-20.68%)
0.5399 USD
-0.09 (-13.89%)
We assign a fundamental rating of 2 out of 10 to LSB. LSB was compared to 531 industry peers in the Biotechnology industry. LSB has a bad profitability rating. Also its financial health evaluation is rather negative. LSB is valued correctly, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
LSB had negative earnings in the past year.
In the past year LSB has reported a negative cash flow from operations.
In the past 5 years LSB always reported negative net income.
In the past 5 years LSB always reported negative operating cash flow.
1.2 Ratios
LSB has a Return On Assets of -7.31%. This is amongst the best in the industry. LSB outperforms 86.30% of its industry peers.
LSB has a better Return On Equity (-20.01%) than 84.81% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.31% | ||
| ROE | -20.01% | ||
| ROIC | N/A |
ROA(3y)-17.48%
ROA(5y)-10.54%
ROE(3y)-44.33%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Gross Margin value of 82.47%, LSB belongs to the best of the industry, outperforming 85.74% of the companies in the same industry.
LSB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 82.48% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
LSB does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for LSB has been increased compared to 1 year ago.
The debt/assets ratio for LSB is higher compared to a year ago.
2.2 Solvency
LSB has an Altman-Z score of -1.99. This is a bad value and indicates that LSB is not financially healthy and even has some risk of bankruptcy.
LSB has a Altman-Z score (-1.99) which is in line with its industry peers.
LSB has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
LSB's Debt to Equity ratio of 0.05 is on the low side compared to the rest of the industry. LSB is outperformed by 60.56% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.99 |
ROIC/WACCN/A
WACC5.01%
2.3 Liquidity
LSB has a Current Ratio of 1.02. This is a normal value and indicates that LSB is financially healthy and should not expect problems in meeting its short term obligations.
LSB has a Current ratio of 1.02. This is amonst the worse of the industry: LSB underperforms 87.22% of its industry peers.
LSB has a Quick Ratio of 1.02. This is a bad value and indicates that LSB is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.75, LSB is not doing good in the industry: 89.44% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.02 | ||
| Quick Ratio | 0.75 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 87.13% over the past year.
Looking at the last year, LSB shows a small growth in Revenue. The Revenue has grown by 7.24% in the last year.
EPS 1Y (TTM)87.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70.82%
Revenue 1Y (TTM)7.24%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%79.55%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
The Revenue is expected to decrease by -19.01% on average over the next years. This is quite bad
EPS Next Y105.67%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year75.61%
Revenue Next 2Y-43.54%
Revenue Next 3Y-29.5%
Revenue Next 5Y-19.01%
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
LSB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 4.39 indicates a rather cheap valuation of LSB.
LSB's Price/Forward Earnings ratio is rather cheap when compared to the industry. LSB is cheaper than 99.07% of the companies in the same industry.
LSB's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 23.69.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 4.39 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
LSB does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
0.627
-0.16 (-20.68%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners0.66%
Inst Owner ChangeN/A
Ins Owners12.67%
Ins Owner ChangeN/A
Market Cap25.84M
Revenue(TTM)614.96M
Net Income(TTM)-99.98M
Analysts80
Price Target31.62 (4943.06%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 4.39 | ||
| P/S | 0.3 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.37 | ||
| P/tB | 0.43 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.73
EYN/A
EPS(NY)0.14
Fwd EY22.79%
FCF(TTM)-0.47
FCFYN/A
OCF(TTM)-0.41
OCFYN/A
SpS2.09
BVpS1.7
TBVpS1.45
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.31% | ||
| ROE | -20.01% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 82.48% | ||
| FCFM | N/A |
ROA(3y)-17.48%
ROA(5y)-10.54%
ROE(3y)-44.33%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.45
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 48.73% | ||
| Cap/Sales | 2.9% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.02 | ||
| Quick Ratio | 0.75 | ||
| Altman-Z | -1.99 |
F-Score4
WACC5.01%
ROIC/WACCN/A
Cap/Depr(3y)103.04%
Cap/Depr(5y)328.9%
Cap/Sales(3y)6.31%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)87.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70.82%
EPS Next Y105.67%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)7.24%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%79.55%
Revenue Next Year75.61%
Revenue Next 2Y-43.54%
Revenue Next 3Y-29.5%
Revenue Next 5Y-19.01%
EBIT growth 1Y82.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year162.66%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y59.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y59.02%
OCF growth 3YN/A
OCF growth 5YN/A
LAKESHORE BIOPHARMA CO LTD / LSB FAQ
Can you provide the ChartMill fundamental rating for LAKESHORE BIOPHARMA CO LTD?
ChartMill assigns a fundamental rating of 2 / 10 to LSB.
What is the valuation status of LAKESHORE BIOPHARMA CO LTD (LSB) stock?
ChartMill assigns a valuation rating of 4 / 10 to LAKESHORE BIOPHARMA CO LTD (LSB). This can be considered as Fairly Valued.
Can you provide the profitability details for LAKESHORE BIOPHARMA CO LTD?
LAKESHORE BIOPHARMA CO LTD (LSB) has a profitability rating of 2 / 10.
Can you provide the expected EPS growth for LSB stock?
The Earnings per Share (EPS) of LAKESHORE BIOPHARMA CO LTD (LSB) is expected to grow by 105.67% in the next year.